- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07774338
Serum sRAGE, CC16, and Syndecan-1 as Predictors of ARDS and Mortality After Severe Chest Trauma
17 agosto 2026 aggiornato da: WTMahran, Assiut University
Early Admission Serum Soluble Receptor for Advanced Glycation End Products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 as Independent Predictors of Acute Respiratory Distress Syndrome and In-Hospital Mortality Following Severe Isolated Chest Trauma: A Prospective Cohort Study.
This prospective cohort study aims to evaluate whether blood levels of soluble receptor for advanced glycation end products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 measured early after severe chest trauma can predict the development of acute respiratory distress syndrome (ARDS) and in-hospital mortality.
Adult patients aged 18 years or older admitted with severe blunt or penetrating chest trauma will be enrolled.
Clinical data, injury severity, laboratory findings, imaging results, and clinical outcomes will be recorded.
Patients will be followed daily during the first 7 days after admission for the development of ARDS, and in-hospital mortality will be recorded until discharge or death.
The findings may help identify patients at high risk of respiratory complications and poor outcomes after severe chest trauma.
Panoramica dello studio
Stato
Non ancora reclutamento
Intervento / Trattamento
Tipo di studio
Osservativo
Iscrizione (Stimato)
85
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Wesam Mahran, Specialist of Emergency Medici
- Numero di telefono: 01028181966
- Email: Wesam.20134479@med.aun.edu.eg
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
No
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
The study population will include adult patients aged 18 years or older admitted to the trauma unit with severe blunt or penetrating chest trauma.
All eligible participants will undergo clinical assessment, routine laboratory and radiological evaluation, and single blood sampling for measurement of serum sRAGE, CC16, and Syndecan-1 levels.
Participants will be followed prospectively for the development of ARDS during the first 7 days after admission, while in-hospital mortality will be recorded until hospital discharge or death.
Descrizione
Inclusion Criteria:
Adult patients aged 18 - 60 years old.
- Patients with blunt or penetrating severe chest trauma.
- Chest Abbreviated Injury Scale (Chest AIS ≥3).
- Admission within 24 hours of injury.
- Patients admitted to the Trauma Unit or Trauma ICU.
- Written informed consent obtained from the patient or legally authorized representative.
Exclusion Criteria:
h. Age below 18 years or above 60 years old (to ensure a homogeneous adult study population and avoid age- related physiological differences).
- i. Hospital admission more than 24 hours after injury (to ensure early biomarker measurement before secondary inflammatory changes occur).
- j. Previous diagnosis of acute respiratory distress syndrome before admission (to ensure that ARDS outcomes are attributable to the index chest trauma).
- k. Pre-existing chronic interstitial lung disease (to avoid baseline pulmonary abnormalities that may influence biomarker levels and respiratory outcomes).
- l. Acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization (to minimize confounding from pre-existing acute pulmonary inflammation).
- m. Active pulmonary infection before trauma (to exclude pre-existing pulmonary inflammation that may alter biomarker levels and increase the risk of ARDS independently of trauma).
- n. End-stage chronic liver disease (to avoid altered inflammatory responses and poor clinical outcomes unrelated to chest trauma).
- o. End-stage renal disease requiring dialysis (to avoid altered clearance of circulating biomarkers and independently increased mortality risk).
- p. Active malignancy receiving chemotherapy or radiotherapy (to exclude patients with cancer-related systemic inflammation and immunosuppression that may affect biomarker levels and outcomes).
- q. Pregnancy (because physiological changes during pregnancy may influence biomarker levels and respiratory function).
- r. Patients transferred from another hospital more than 24 hours after injury (to ensure standardized early clinical assessment and biomarker sampling within the predefined study period).
- s. Refusal to participate in the study (because informed consent is required for study enrollment).
- t. Connective tissue diseases
- u. Severe burns and major inhalational injury v. Immunosuppressive therapy
- w. Chronic systemic inflammatory diseases
- x. Severe obesity ( BMI>40), if relevant.
- y. Poly trauma with AIS> or = 3 outside the chest.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Severe Chest Trauma Cohort
Adults aged 18 years or older with severe blunt or penetrating chest trauma admitted to the trauma unit and enrolled in the study.
Participants will be followed prospectively for the development of acute respiratory distress syndrome and in-hospital mortality.
|
No intervention is assigned.
Participants receive standard clinical care, and the study prospectively observes clinical outcomes and biomarkers following severe chest trauma.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Development of acute respiratory distress syndrome (ARDS), diagnosed according to the 2024 Global Definition of ARDS.
Lasso di tempo: From admission through 7 days
|
Acute respiratory distress syndrome (ARDS) will be diagnosed according to the 2024 Global Definition of ARDS, which updates and expands the Berlin Definition.
ARDS is defined by acute hypoxemic respiratory failure occurring within one week of a known clinical insult, with bilateral pulmonary opacities on chest imaging (chest radiography, computed tomography, or lung ultrasound) not fully explained by cardiac failure or fluid overload, and impaired oxygenation (PaO₂/FiO₂ ≤300 mmHg or SpO₂/FiO₂ ≤315 under specified respiratory support).
Severity is classified as mild, moderate, or severe according to the degree of hypoxemia).
Two independent intensivists blinded to biomarker results will independently adjudicate ARDS diagnosis according to the 2024 Global Definition Two independent intensivists blinded to biomarker results will independently adjudicate ARDS diagnosis according to the 2024 Global Definition
|
From admission through 7 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
In-hospital mortality.
Lasso di tempo: From hospital admission until hospital discharge or death, whichever occurs first, assessed up to 28 days after admission.
|
From hospital admission until hospital discharge or death, whichever occurs first, assessed up to 28 days after admission.
|
|
|
ICU length of stay.
Lasso di tempo: From ICU admission until ICU discharge or death, with the outcome assessed up to 28 days after ICU admission.
|
From ICU admission until ICU discharge or death, with the outcome assessed up to 28 days after ICU admission.
|
|
|
Need for invasive mechanical ventilation
Lasso di tempo: Assessed daily from hospital admission through Day 7, or until initiation of invasive mechanical ventilation, hospital discharge, or death, whichever occurs first.
|
Requirement for invasive mechanical ventilation during hospitalization following severe chest trauma.
|
Assessed daily from hospital admission through Day 7, or until initiation of invasive mechanical ventilation, hospital discharge, or death, whichever occurs first.
|
|
Duration of mechanical ventilation.
Lasso di tempo: From initiation of invasive mechanical ventilation through Day 7, with assessment daily until successful extubation, death, hospital discharge, or Day 7, whichever occurs first.
|
From initiation of invasive mechanical ventilation through Day 7, with assessment daily until successful extubation, death, hospital discharge, or Day 7, whichever occurs first.
|
|
|
Hospital length of stay.
Lasso di tempo: From hospital admission until hospital discharge or death, with hospital length of stay assessed up to 28 days after admission.
|
From hospital admission until hospital discharge or death, with hospital length of stay assessed up to 28 days after admission.
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD, Brochard LJ, Calfee CS, Combes A, Daniel BM, Ferguson ND, Gong MN, Gotts JE, Herridge MS, Laffey JG, Liu KD, Machado FR, Martin TR, McAuley DF, Mercat A, Moss M, Mularski RA, Pesenti A, Qiu H, Ramakrishnan N, Ranieri VM, Riviello ED, Rubin E, Slutsky AS, Thompson BT, Twagirumugabe T, Ware LB, Wick KD. A New Global Definition of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2024 Jan 1;209(1):37-47. doi: 10.1164/rccm.202303-0558WS.
- Jabaudon M, Berthelin P, Pranal T, Roszyk L, Godet T, Faure JS, Chabanne R, Eisenmann N, Lautrette A, Belville C, Blondonnet R, Cayot S, Gillart T, Pascal J, Skrzypczak Y, Souweine B, Blanchon L, Sapin V, Pereira B, Constantin JM. Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study. Sci Rep. 2018 Feb 8;8(1):2603. doi: 10.1038/s41598-018-20994-x.
- Bime C, Camp SM, Casanova N, Oita RC, Ndukum J, Lynn H, Garcia JGN. The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility. Transl Res. 2020 Dec;226:105-115. doi: 10.1016/j.trsl.2020.06.010. Epub 2020 Jun 26.
- Gao J, Rao T, Li Y, Gu W, Lu Q. Acute lung injury induced by traumatic hemorrhagic shock: pathogenesis, biomarkers and therapeutic perspectives. World J Emerg Med. 2025 Nov 1;16(6):532-542. doi: 10.5847/wjem.j.1920-8642.2025.119.
- Xie WW, Ding YJ, Bhandari S, Li H, Chen HS, Jin SW, Weng HX, Hao Y. CLINICAL VALUE OF SYNDECAN-1 LEVELS IN TRAUMA BRAIN INJURY: A META-ANALYSIS. Shock. 2024 Jan 1;61(1):49-54. doi: 10.1097/SHK.0000000000002255. Epub 2023 Oct 12.
- Negrin LL, Halat G, Kettner S, Gregori M, Ristl R, Hajdu S, Heinz T. Club cell protein 16 and cytokeratin fragment 21-1 as early predictors of pulmonary complications in polytraumatized patients with severe chest trauma. PLoS One. 2017 Apr 5;12(4):e0175303. doi: 10.1371/journal.pone.0175303. eCollection 2017.
- Jabaudon M, Blondonnet R, Roszyk L, Bouvier D, Audard J, Clairefond G, Fournier M, Marceau G, Dechelotte P, Pereira B, Sapin V, Constantin JM. Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2015 Jul 15;192(2):191-9. doi: 10.1164/rccm.201501-0020OC.
- Ahs EF, Gunther M. Biomarkers in Traumatic Lung Injury - A Systematic Review. J Surg Res. 2026 May;321:127-142. doi: 10.1016/j.jss.2026.02.018. Epub 2026 Mar 20.
- Dixon A, Kenny JE, Buzzard L, Holcomb J, Bulger E, Wade C, Fabian T, Schreiber M; PROPPR Study Group. Acute respiratory distress syndrome, acute kidney injury, and mortality after trauma are associated with increased circulation of syndecan-1, soluble thrombomodulin, and receptor for advanced glycation end products. J Trauma Acute Care Surg. 2024 Feb 1;96(2):319-325. doi: 10.1097/TA.0000000000004096. Epub 2023 Sep 6.
- Wei Y, Ren X, Yuan Z, Hong J, Wang T, Chen W, Xu Y, Ding J, Lin J, Jiang W, Zhang P, Wu Q. Trauma diagnostic-related target proteins and their detection techniques. Expert Rev Mol Med. 2024 Apr 11;26:e7. doi: 10.1017/erm.2024.3.
- Lin H, Liu Q, Zhao L, Liu Z, Cui H, Li P, Fan H, Guo L. Circulating Pulmonary-Originated Epithelial Biomarkers for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023 Mar 23;24(7):6090. doi: 10.3390/ijms24076090.
- Ma W, Tang S, Yao P, Zhou T, Niu Q, Liu P, Tang S, Chen Y, Gan L, Cao Y. Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies. Signal Transduct Target Ther. 2025 Mar 7;10(1):75. doi: 10.1038/s41392-025-02127-9.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
1 ottobre 2026
Completamento primario (Stimato)
1 ottobre 2028
Completamento dello studio (Stimato)
1 dicembre 2028
Date di iscrizione allo studio
Primo inviato
12 agosto 2026
Primo inviato che soddisfa i criteri di controllo qualità
17 agosto 2026
Primo Inserito (Effettivo)
19 agosto 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
19 agosto 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
17 agosto 2026
Ultimo verificato
1 agosto 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Chest trauma Assiut2026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data will not be shared with other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .